Cardioxyl Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 31 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Cardioxyl ranks #9,992 of 49,997 tracked US assignees by granted-patent volume, with 31 patents across 6 technology areas.
- #9,992
- of 49,997 US assignees by volume
- Top 47%
- by Innovation Score (36.2/100)
- 21.4
- avg claims per patent
- -57%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R9992 · US Corporation #9,992 · 31 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-SMALL 31 grants
- UPPER-Q #9,992/49,997
- PHOTO-FINISH Calysta
- CPC-NARROW A61P · 6 areas
- INNOV-THIN 36.2/100
- CLAIMS-DENSE 21.4 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -57% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Calysta, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Cardioxyl’s 36.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Cardioxyl
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Express Scripts · near
Express Scripts · near
36 score
- Swatch · near
Swatch · near
36 score
- Cardioxyl Pharmaceut… · this assignee
Cardioxyl Pharmaceut… · this assignee
36 score
- I C Medical · near
I C Medical · near
36 score
- Restor3d · near
Restor3d · near
36 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Cardioxyl's Innovation Score is 36.2/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Cardioxyl?
Each dot is one of Cardioxyl’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cardioxyl’s own 21.4 claims/patent is ABOVE the 17.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Cardioxyl's grants concentrate
Cardioxyl Pharmaceuticals, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (6 grants) versus a trough of 1 in 2023. By volume, Cardioxyl sits between Control Techniques Limited and Crane & Co., Inc..
Cardioxyl's three-year grant acceleration
Cardioxyl Pharmaceuticals, Inc. shows 4 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Cardioxyl's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Control Techniques
Control Techniques Limited
31 patents
- Curt Manufacturing
Curt Manufacturing, LLC
31 patents
- Calysta
Calysta, Inc.
31 patents
- Cardiac Dimension…
Cardiac Dimensions Pty. Ltd.
31 patents
- Celestial AI
Celestial AI Inc.
31 patents
- Channel Medsystems
Channel Medsystems, Inc.
31 patents
- Chrysler Group
Chrysler Group LLC
31 patents
- Crane &
Crane & Co., Inc.
31 patents
- Cardioxyl Pharmac… ◀
Cardioxyl Pharmaceuticals, Inc.
31 patents
What this shows Cardioxyl holds 31 patents at rank #10,004, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Cardioxyl
By rank, the assignees closest to #10,004 in granted patent volume.
- Control Techniques Limited #10,000 · 31 patents
- Curt Manufacturing, LLC #10,001 · 31 patents
- Calysta, Inc. #10,002 · 31 patents
- Cardiac Dimensions Pty. Ltd. #10,003 · 31 patents
- Celestial AI Inc. #10,005 · 31 patents
- Channel Medsystems, Inc. #10,006 · 31 patents
- Chrysler Group LLC #10,007 · 31 patents
- Crane & Co., Inc. #10,008 · 31 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Cardioxyl's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Cardioxyl, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Cardioxyl ranks #634 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (36 here).
Cardioxyl's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
36 Top 47% higher than 53% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 16.1% |
| 2016 | 2 | 6.5% |
| 2017 | 6 | 19.4% |
| 2018 | 3 | 9.7% |
| 2019 | 5 | 16.1% |
| 2020 | 5 | 16.1% |
| 2022 | 3 | 9.7% |
| 2023 | 1 | 3.2% |
| 2025partial year | 1 | 3.2% |
Which technologies does Cardioxyl Pharmaceuticals, Inc. patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Cardioxyl Pharmaceuticals, Inc.'s patent record in context - here's where to go next.
- Cardioxyl Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #9,992 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Cardioxyl Pharmaceuticals, Inc. against Control Techniques Limited, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 36.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.